查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1698253

磺达肝癸钠市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

Fondaparinux Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 132 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球磺达肝癸钠市值为 6.919 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 6.8%。市场扩张的动力在于深部静脉栓塞 (DVT) 和肺栓塞 (PE) 等血栓栓塞性疾病发生率的增加，以及对有效抗凝血疗法的偏好日益增长。磺达肝癸钠是一种合成抗凝血剂，在预防和治疗血栓方面发挥至关重要的作用，它具有针对性的作用机制，并降低了肝素诱发併发症的风险。包括骨科手术在内的外科手术数量的不断增加，进一步推动了对抗凝血治疗的需求，巩固了磺达肝癸钠作为该领域主要参与者的地位。医疗保健基础设施的扩张和具有成本效益的治疗方案的增加继续支持市场成长。此外，有利的监管政策和对先进抗凝血疗法的推动加强了磺达肝癸钠在住院和门诊环境中的应用。

磺达肝癸钠市场 - IMG1

磺达肝癸钠市场分为品牌药和仿製药，其中仿製药由于价格低廉、使用广泛而占据主导地位。 2024 年，仿製药部门创造了 4.393 亿美元的收入，凸显了其强大的市场地位。随着医疗保健提供者和患者寻求品牌药物的经济有效的替代品，特别是在需要长期抗凝血治疗的情况下，对仿製磺达肝癸钠的需求持续上升。随着越来越多的患者需要持续预防血栓，仿製药提供了一种方便且经济实惠的解决方案，推动了医院、诊所和家庭护理机构的采用。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 6.919亿美元
预测值 13.2亿美元
复合年增长率 6.8%

依应用细分显示，磺达肝癸钠广泛用于治疗深部静脉栓塞 (DVT)、肺栓塞 (PE) 和急性冠状动脉综合征 (ACS)。 2024 年，DVT 领域占据了 47.8% 的市场份额，反映出全球 DVT 病例的盛行率不断上升。老年人和患有慢性疾病的人面临更高的血栓形成风险，因此有效的抗凝血治疗至关重要。由于其疗效可靠、药物动力学可预测，且与某些传统抗凝血剂不同，不需要常规血液监测，因此磺达肝癸钠仍是一种首选治疗方法。

2024 年，美国磺达肝癸钠市场产值达 2.443 亿美元，预计到 2034 年将达到 4.339 亿美元。促成这一扩张的因素有很多，包括大量的骨科手术、人口老化以及需要抗凝血治疗的重大疾病盛行率上升。先进治疗方案的日益普及以及对更安全、更有效的抗凝血剂的需求继续推动磺达肝癸钠在美国市场的地位，加强其在现代医疗保健中的作用。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

  • 产业生态系统分析
  • 产业衝击力
    • 成长动力
      • 血栓栓塞性疾病发生率上升
      • 髋关节和膝关节移植手术增加
      • 全球老龄人口激增
    • 产业陷阱与挑战
      • 与磺达肝癸钠相关的副作用
  • 成长潜力分析
  • 监管格局
  • 管道分析
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL 分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 策略仪表板

第五章：市场估计与预测：依产品类型，2021 年至 2034 年

  • 主要趋势
  • 品牌
  • 通用的

第六章：市场估计与预测：按应用，2021 年至 2034 年

  • 主要趋势
  • 深层静脉栓塞
  • 肺栓塞
  • 急性冠状动脉综合症
  • 其他应用

第七章：市场估计与预测：按配销通路，2021 年至 2034 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第八章：市场估计与预测：按地区，2021 年至 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋

第九章：公司简介

  • Abbott Laboratories
  • Alchemia
  • Apotex
  • Aurobindo
  • Dr. Reddy's Laboratories
  • Jiangsu Hengrui Medicine
  • Lupin Pharmaceuticals
  • Sandoz
  • ScinoPharm Taiwan
  • Viatris
简介目录
Product Code: 13234

The Global Fondaparinux Market was valued at USD 691.9 million in 2024 and is projected to expand at a CAGR of 6.8% between 2025 and 2034. The market expansion is fueled by the increasing incidence of thromboembolic disorders such as deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the growing preference for effective anticoagulation therapies. Fondaparinux, a synthetic anticoagulant, plays a vital role in preventing and treating blood clots, offering a targeted mechanism of action with a lower risk of heparin-induced complications. The rising number of surgical procedures, including orthopedic surgeries, further propels the demand for anticoagulant treatments, solidifying fondaparinux's position as a key player in this segment. The expansion of healthcare infrastructure and the increased availability of cost-effective treatment options continue to support market growth. Additionally, favorable regulatory policies and the push for advanced anticoagulant therapies reinforce fondaparinux's adoption across inpatient and outpatient settings.

Fondaparinux Market - IMG1

The fondaparinux market is divided into branded and generic versions, with the generic segment maintaining a dominant position due to its affordability and widespread use. In 2024, the generic segment generated USD 439.3 million in revenue, highlighting its strong market presence. The demand for generic fondaparinux continues to rise as healthcare providers and patients seek cost-effective alternatives to branded drugs, particularly in cases requiring long-term anticoagulation therapy. With an increasing number of patients requiring continued blood clot prevention, generic formulations provide an accessible and budget-friendly solution, driving adoption across hospitals, clinics, and home care settings.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$691.9 Million
Forecast Value$1.32 Billion
CAGR6.8%

Segmentation by application reveals that fondaparinux is widely used for treating deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndrome (ACS). In 2024, the DVT segment accounted for 47.8% of the market, reflecting the growing prevalence of DVT cases worldwide. Older adults and individuals with chronic health conditions face higher risks of clot formation, making effective anticoagulation therapy essential. Fondaparinux remains a preferred treatment due to its reliable efficacy, predictable pharmacokinetics, and the advantage of not requiring routine blood monitoring, unlike certain traditional anticoagulants.

The U.S. fondaparinux market generated USD 244.3 million in 2024 and is projected to reach USD 433.9 million by 2034. Several factors contribute to this expansion, including a high volume of orthopedic procedures, an aging population, and a rising prevalence of critical illnesses that necessitate anticoagulation therapy. The increasing adoption of advanced treatment protocols and the demand for safer, more efficient anticoagulants continue to drive fondaparinux's market presence in the U.S., reinforcing its role in modern healthcare.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of thromboembolic diseases
      • 3.2.1.2 Increase in hip and knee transplant surgeries
      • 3.2.1.3 Surge in aging population worldwide
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Side effects associated with fondaparinux
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter’s analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Branded
  • 5.3 Generic

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Deep vein thrombosis
  • 6.3 Pulmonary embolism
  • 6.4 Acute coronary syndrome
  • 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospital pharmacies
  • 7.3 Retail pharmacies
  • 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 India
    • 8.4.3 Japan
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 South Africa
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 Alchemia
  • 9.3 Apotex
  • 9.4 Aurobindo
  • 9.5 Dr. Reddy’s Laboratories
  • 9.6 Jiangsu Hengrui Medicine
  • 9.7 Lupin Pharmaceuticals
  • 9.8 Sandoz
  • 9.9 ScinoPharm Taiwan
  • 9.10 Viatris